U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H40O3
Molecular Weight 412.6047
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 3
Charge 0

SHOW SMILES / InChI
Structure of CALCIPOTRIENE

SMILES

C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]2CC[C@@H]3[C@]2(C)CCC\C3=C/C=C4/C[C@@H](O)C[C@H](O)C4=C

InChI

InChIKey=LWQQLNNNIPYSNX-UROSTWAQSA-N
InChI=1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24+,25-,26+,27-/m1/s1

HIDE SMILES / InChI

Molecular Formula C27H40O3
Molecular Weight 412.6047
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 3
Optical Activity UNSPECIFIED

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Curative
DOVONEX

Approved Use

Calcipotriene Cream, 0.005%, is indicated for the treatment of plaque psoriasis. The safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established.

Launch Date

1993
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
55.9 pg/mL
0.005 % 1 times / day multiple, topical
dose: 0.005 %
route of administration: Topical
experiment type: MULTIPLE
co-administered: BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
24.4 pg/mL
0.005 % 1 times / day multiple, topical
dose: 0.005 %
route of administration: Topical
experiment type: MULTIPLE
co-administered: BETAMETHASONE DIPROPIONATE
MC1080 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
82.5 pg × h/mL
0.005 % 1 times / day multiple, topical
dose: 0.005 %
route of administration: Topical
experiment type: MULTIPLE
co-administered: BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
59.3 pg × h/mL
0.005 % 1 times / day multiple, topical
dose: 0.005 %
route of administration: Topical
experiment type: MULTIPLE
co-administered: BETAMETHASONE DIPROPIONATE
MC1080 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 20.8 uM]
yes [IC50 37.9 uM]
yes [IC50 6 uM]
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Vitamin D Analogs Potentiate the Antitumor Effect of Imatinib Mesylate in a Human A549 Lung Tumor Model.
2015-11-13
Synergistic induction of human cathelicidin antimicrobial peptide gene expression by vitamin D and stilbenoids.
2014-03
The atopic dermatitis-like symptoms induced by MC903 were alleviated in JNK1 knockout mice.
2013-12
Synthesis and Biological Activity of Diastereomeric and Geometric Analogs of Calcipotriol, PRI-2202 and PRI-2205, Against Human HL-60 Leukemia and MCF-7 Breast Cancer Cells.
2013-10-31
Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model.
2013-06-18
Calcipotriol induces autophagy in HeLa cells and keratinocytes.
2011-04
Hypercalcemia caused by vitamin D3 analogs in psoriasis treatment.
2007-12
Effect of topical vitamin D analogue on in vivo contact sensitization.
2006-10
Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis.
2006-08-01
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005-06
Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis.
2005-05
Severe hypercalcemia and hypernatremia associated with calcipotriol for treatment of psoriasis.
2004
Nonpsoriatic uses of calcipotriol.
2002-08-28
The use of topical calcipotriene/calcipotriol in conditions other than plaque-type psoriasis.
1997-09
Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis.
1996-03
Cytotoxic effects of 1 alpha,25-dihydroxyvitamin D3 and synthetic vitamin D3 analogues on a glioma cell line.
1996-02-27
Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
1995-01
Calcipotriol inhibits rectal epithelial cell proliferation in ulcerative proctocolitis.
1994-12
Profile of ligand specificity of the vitamin D binding protein for 1 alpha,25-dihydroxyvitamin D3 and its analogs.
1994-08
Hypercalcaemia during treatment of psoriasis with calcipotriol.
1994-06
Hypercalcaemic crisis after excessive topical use of a vitamin D derivative.
1994-03
Hypercalcaemia associated with calcipotriol (Dovonex) treatment.
1993-04-03
Effects of 1 alpha,25-dihydroxy-vitamin D3 and calcipotriol on organotypic cultures of outer root sheath cells: a potential model to evaluate antipsoriatic drugs.
1993
Patents

Sample Use Guides

Apply a thin layer of Dovonex Cream to the affected skin twice daily and rub in gently and completely. The safety and efficacy of Dovonex Cream have been demonstrated in patients treated for eight weeks.
Route of Administration: Topical
The immune modulatory effects of betamethasone, calcipotriol and the combination in ex vivo cultures of psoriatic skin and in vitro cultures of primary human cells that recapitulate key cellular activities of psoriatic inflammation were investigated and compared.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:13:26 GMT 2025
Edited
by admin
on Mon Mar 31 18:13:26 GMT 2025
Record UNII
143NQ3779B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CALCIPOTRIOL
INN   JAN   MART.   WHO-DD  
INN  
Preferred Name English
CALCIPOTRIENE
MI   ORANGE BOOK   USAN   USP-RS   VANDF  
USAN  
Official Name English
MC-903
Code English
(5Z,7E,22E,24S)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1?,3?,24-triol
Common Name English
calcipotriol [INN]
Common Name English
CALCIPOTRIOL [JAN]
Common Name English
CALCIPOTRIENE [USP MONOGRAPH]
Common Name English
SORILUX
Brand Name English
9,10-SECOCHOLA-5,7,10(19),22-TETRAENE-1,3,24-TRIOL, 24-CYCLOPROPYL-, (1.ALPHA.,3.BETA.,5Z,7E,22E,24S)-
Common Name English
CALCIPOTRIOL ANHYDROUS
EP  
Common Name English
CALCIPOTRIOL [EP MONOGRAPH]
Common Name English
CALCIPTRIOL
Common Name English
CALCIPOTRIENE [MI]
Common Name English
Calcipotriol [WHO-DD]
Common Name English
CALCIPOTRIENE [USAN]
Common Name English
CALCIPOTRIENE [ORANGE BOOK]
Common Name English
CALCIPOTRIENE [VANDF]
Common Name English
DOVONEX
Brand Name English
CALCIPOTRIENE [USP-RS]
Common Name English
PRI-2201
Code English
CALCIPOTRIOL [MART.]
Common Name English
Classification Tree Code System Code
NDF-RT N0000006277
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
NDF-RT N0000175849
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
WHO-VATC QD05AX52
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
WHO-ATC D05AX02
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
NCI_THESAURUS C29708
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
WHO-ATC D05AX52
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
WHO-VATC QD05AX02
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
Code System Code Type Description
WIKIPEDIA
CALCIPOTRIOL
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
PRIMARY
DAILYMED
143NQ3779B
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
PRIMARY
FDA UNII
143NQ3779B
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
PRIMARY
EVMPD
SUB06046MIG
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
PRIMARY
CAS
112828-00-9
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
SUPERSEDED
LACTMED
Calcipotriene
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
PRIMARY
MERCK INDEX
m2914
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
PRIMARY Merck Index
EPA CompTox
DTXSID0046648
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
PRIMARY
RS_ITEM_NUM
1086141
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
PRIMARY
NCI_THESAURUS
C28900
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
PRIMARY
MESH
C055085
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
PRIMARY
USAN
CC-76
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
PRIMARY
PUBCHEM
5288783
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
PRIMARY
ChEMBL
CHEMBL1200666
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
PRIMARY
CAS
112965-21-6
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
PRIMARY
EVMPD
SUB22029
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
PRIMARY
INN
6376
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
PRIMARY
DRUG BANK
DB02300
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
PRIMARY
IUPHAR
2778
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
PRIMARY
RXCUI
29365
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
PRIMARY RxNorm
SMS_ID
100000085642
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
PRIMARY
DRUG CENTRAL
465
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
PRIMARY
CHEBI
50749
Created by admin on Mon Mar 31 18:13:26 GMT 2025 , Edited by admin on Mon Mar 31 18:13:26 GMT 2025
PRIMARY
Related Record Type Details
SOLVATE->ANHYDROUS
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Calcipotriene impurity G and calcipotriene impurity H not more than 0.25%
CHROMATOGRAPHIC PURITY (TLC)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Calcipotriene impurity G and calcipotriene impurity H not more than 0.25%
CHROMATOGRAPHIC PURITY (TLC)
USP
Related Record Type Details
ACTIVE MOIETY